BiotechTube
Home/Pipeline/ALE.P03

ALE.P03

Not Specified

PreclinicalActive

Key Facts

Indication
Not Specified
Phase
Preclinical
Status
Active
Company
Alentis Therapeutics

About Alentis Therapeutics

Alentis Therapeutics is a private, clinical-stage biotechnology company headquartered in Basel, Switzerland, and is a leader in targeting Claudin-1 (CLDN1). Its pipeline includes the ADC ALE.P02 for squamous cancers and the monoclonal antibody lixudebart (ALE.F02) for organ fibrosis, both in clinical development. The company was founded on over 15 years of foundational research and is led by a seasoned team, including CEO Mark Pruzanski, a veteran biotech entrepreneur. Alentis aims to address significant unmet needs in oncology and fibrotic diseases through its novel Claudin-1-targeting platform.

View full company profile

Therapeutic Areas

OncologyFibrosis

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved